0 of 9 questions completed
Questions:
You have already completed the assessment before. Hence you can not start it again.
Assessment is loading…
You must sign in or sign up to start the assessment.
You must first complete the following:
0 of 9 questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Which of the below statements is a result of a study of CTL119 in CLL relapsed/refractory patients previously treated with ibrutinib:
In a study of CTL119 in CLL relapsed/refractory patients previously treated with ibrutinib, the authors concluded all except:
Concurrent ibrutinib administration worsens outcomes and increases toxicity of CAR T-cell therapy in relapsed or refractory CLL:
A limitation of use of approved CAR T –cell therapies in treating DLBCL patients is:
One “lesson learned” in treating DLBCL patients is:
Some question(s) that remain concerning treatment of DLBCL patients with CAR T-cell therapy include:
Severity of CRS correlates with all of the following except:
ASBMT cytokine release grading includes:
Immune Effector Encephalopathy (ICE) grading differs from CARTOX-10 grading for neurotoxicity by: